Sham Mailankody, MBBS, on Further Research With ALLO-715

“Can we understand why some patients have a long response and others don't? Can we understand the importance of antigen BCMA expression at baseline and at the time of relapse, and correlations with how high the CAR T expands? How long do the cells persist? Some of this is data that we're currently trying to generate to try and better understand how we can get more patients with these2+year responses.”

ALLO-715 (Allogene), an allogeneic anti-BCMA chimeric antigen receptor (CAR) T-cell therapy, had a manageable safety profile with promising efficacy in patients with relapsed/refractory multiple myeloma (R/R MM) in the phase 1 UNIVERSAL open-label trial (NCT04093596). These data, which includedan objective response rate of 65% and a very good partial response rate of about 50%, were presented by Sham Mailankody, MBBS, associate attending physician, Memorial Sloan Kettering Cancer Center, 64th American Society of Hematology (ASH) Annual Meeting, held December 10-12, 2022, in New Orleans, Louisiana.

CGTLive spoke with Mailankody to learn more about ALLO-715 and research that remains to be done and questions that remain to be answered with the therapy and with cell therapy for R/R MM in general. He also discussed advantages of allogeneic therapies over autologous therapies.

REFERENCE

2019 Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma. Presented at: 64th ASH Annual Meeting, December 10-12, 2022, in New Orleans, Louisiana. Abstract #2019.